Met Non Small Cell Cancer Registry (MOMENT)
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
EMD Serono Research & Development Institute, Inc.
700 participants
Oct 4, 2022
OBSERVATIONAL
Conditions
Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Eligibility
Inclusion Criteria3
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
Exclusion Criteria1
- Participants who are enrolled in a clinical trial
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(64)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05376891